Biocryst Pharmaceuticals buy Cantor Fitzgerald
Start price
29.04.25
/
50%
€7.44
Target price
29.04.26
€17.56
Performance (%)
-26.31%
Price
30.01.26
€5.55
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -26.31%. This prediction currently runs until 29.04.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -3.479% | -3.479% |
| iShares Core DAX® | -1.432% | 0.000% |
| iShares Nasdaq 100 | -0.386% | -0.595% |
| iShares Nikkei 225® | 1.448% | 5.269% |
| iShares S&P 500 | 0.114% | -0.217% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $20.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.72
15.10.25
15.10.25
€22.38
15.10.26
15.10.26
-3.01%
30.01.26
30.01.26
